Key facts
- This page summarizes Stephen Bardin's Form 4 filing for ATAI Life Sciences N.V. (ATAI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Mar 2023, 20:23.
Stephen Bardin - 14 Mar 2023 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ATAI
- Reported as of
- 14 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Mar 2023, 20:23:11 UTC
- Prior SEC filing
- 17 Aug 2022
- Next SEC filing
- 15 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ryan Barrett, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen Bardin filed Form 4 for ATAI Life Sciences N.V. (ATAI) on 16 Mar 2023.
Change
- Previous filing in this sequence was filed on 17 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ATAI
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +600,000
- Change %
- Price
- $0.000000
- Shares after
- 600,000
- Date
- 14 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 600,000
- Exercise price
- $1.18
- Footnotes
- F1
ATAI
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +350,000
- Change %
- Price
- $0.000000
- Shares after
- 350,000
- Date
- 14 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 350,000
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The stock option shall vest as to 25% of the underlying shares on March 14, 2024, and in 36 substantially equal monthly installments thereafter.
Footnote F2
Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.